-
In war-split Myanmar 'spirit consorts' commune across divide
-
Number of missing in Nepal, China floods soars past 2,400
-
Leaders of Russia, China, Iran to attend summit in Kyrgyzstan
-
Trump announces deal for huge US stake in Venezuelan oil reserves
-
Hovland and Gerard share lead at Tour Championship
-
Kane confirms talks on Bayern extension
-
Maresca salutes 'unbelievable' Cherki after Man City star sinks Palace
-
Trump govt. mulls deal to give away part of Yosemite park
-
Marquinhos rescues last-gasp draw for PSG at Lille in Ligue 1
-
Indian release of Sonia Gandhi memoir uncertain after publisher clarification
-
ICE detains British far-right activist Milo Yiannopoulos in Louisiana
-
Cities show cleaner transport policies can reduce severe air pollution
-
Milo Yiannopoulos held by ICE after missing immigration hearing
-
Four patients harmed in Nashville hospital medication mix-up
-
Six Flags closes X2 rollercoaster after reports of severe brain injuries
-
Essex council hires private guards as Wethersfield asylum centre expands
-
Jury ends second day without verdict in Lindsay Clancy murder trial
-
Haakon VIII becomes Norway's king after Harald V dies at 89
-
Artist says criticised Ronnie O'Sullivan mural is unfinished
-
Six injured after sign falls at Christian festival in West Sussex
-
UAE grants Starlink 10-year satellite broadband licence
-
Dubai airport expands scanners that keep laptops and liquids in bags
-
US says Hormuz mines cleared as diplomacy and military deployments continue
-
Kuwait and Pakistan sign military cooperation agreement
-
Nepal-Tibet flood toll reaches 584 as more than 2,400 remain missing
-
Ramos strikes as AC Milan beat Venezia
-
Cherki makes his point to Maresca as Man City sparkle in Palace rout
-
Odisha faces very heavy rain as Sri Ganganagar reaches 41.4C
-
COP17 soil assessment links worsening land degradation to food and nutrition risks
-
Scammers in China exploit Microsoft Teams and other workplace apps to target victims
-
Medical AI paper predicts autonomous systems could outperform doctors in core clinical tasks by 2030
-
GSA employees report mice, ceiling damage and cloudy water after Washington office move
-
REI Labor Day sale runs through September 7 with outdoor gear discounts
-
Cara and former scraper develop open-source tool to alert artists when work appears in AI datasets
-
Meta tests robots for cabling, server resets and maintenance inside data centers
-
Google expands easier file sharing between Android phones and Apple devices
-
Nepal-Tibet flood rescue resumes after overflowing debris lake forces temporary withdrawal
-
UK chefs turn to induction cooking to reduce kitchen heat, energy use and pollution
-
Extreme heat exposes vulnerabilities across Britain's rail network
-
Restored Cheshire wetland becomes key UK breeding site for black-necked grebes
-
Dollar rallies after Fed chief lifts rate expectations
-
Bayern steamroll Stuttgart in Bundesliga opener
-
Slumping Sabalenka 'confident' ahead of US Open three-peat bid
-
England pace quartet might keep Archer going until he is 40
-
Aston Villa seal swoop for Chelsea striker Jackson
-
Driven by distraction? Trump steps up stunts as US midterms loom
-
Number of missing in deadly Nepal, China floods jumps past 2,400
-
Springboks a wounded beast, warns All Blacks captain Savea
-
Birmingham City Seek First Championship Win Against Wrexham
-
Trump announces new US 'Space Academy'
Biorasi Unveils New Website to Drive Sponsor Success with Biotech-Centric Strategies and Modular CRO Solutions
Relaunch puts customized CRO services front and center for today's Biotech and Biopharma innovators.
AVENTURA, FL / ACCESS Newswire / October 8, 2025 / Biorasi, a leading global full-service contract research organization (CRO), has relaunched its website to reflect a bold new direction: Empowering biotech sponsors with modular clinical trial solutions, AI-powered tools, and a renewed focus on sponsor-centric strategy.
"The future of clinical research belongs to those who can adapt, innovate, and deliver," said Chris O'Brien, CEO of Biorasi. "Our new website reflects a strategic evolution - one that puts biotech sponsors at the center of smarter, faster, and more flexible trials. It's a touchstone for the modular solutions and AI-powered tools that will define the next era of clinical success."
Key updates to the website include:
Focused Study Solutions: Critical standalone service offerings deliver the same high-performance features found in Biorasi's full-service strategies:
Study Rescue and Recovery Packages: Designed to salvage struggling clinical trials and restore timelines.
Flexible Data Sciences Solutions: Advanced analytics and biostatistics available as standalone services.
Specialized Services: Including Quality Assurance, Clinical Monitoring, and Safety & Pharmacovigilance, tailored to sponsor needs.
Accelerated Startup Modules: Fast-track solutions for trials requiring rapid market entry.
AI-Powered Feasibility: Dynamic clinical site modeling combined with targeted feasibility outreach and enrollment forecasting.
New Sponsor Strategy: A sharpened focus on the CRO competencies that matter most: Reliability, Flexibility, and Accessibility.
The redesigned website celebrates Biorasi's over two decades of industry leadership, clinical trial experience, and operational excellence:
Over 200 global studies executed.
Five FDA approvals in the past seven years.
$150M+ in recovered rescue studies.
6 weeks or less for database go-live.
Kickoff Meetings in 10 business days after LOI/WO.
60% repeat business from returning sponsors.
Studies conducted in 48 countries, reaching 65% of the global population.
About Biorasi
Biorasi is a global clinical research organization (CRO) that delivers speed-to-market strategies for small to midsized biotech and biopharma sponsors. With over two decades of expertise in running clinical trials across dermatology, oncology, neurology, nephrology, and other key therapeutic areas, Biorasi leverages reliable, flexible, and accessible solutions necessary to succeed in today's dynamic and evolving clinical trials industry. Contact Biorasi at [email protected] / (786) 388-0700.
SOURCE: Biorasi, LLC
View the original press release on ACCESS Newswire
A.O.Scott--AT